risks of glp 1 agonists The cardiovascular effects GLP-1 receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action Benefits and Risks of GLP-1

Yanovski, J.A

Novo Nordisks Wegovy pill, the first weight-loss drug to win approval from the agency, is expected to launch in the US in early 2026

The specific criteria for inclusion and exclusion of relevant studies in terms of PI(E)COS (Population, Intervention/Exposure, Comparison, Outcomes, and Study design) are provided in Table 1

Recently, the MET-097i candidate was originally developed for once-weekly administration, but its extended half-life also qualifies it for once-monthly dosing [62]

The launch of oral GLP-1s coupled with lower prices and broader access (including Medicare and Medicaid coverage in the U.S.) should drive higher utilization and market penetration as more affordable and convenient options become available. Chris Schott Senior Analyst covering the U.S